Lauxera Capital Closes €400 Million Health Tech Fund to Fuel Europe’s Global Innovation

Lauxera Capital, a Paris-based growth-stage investment firm led by partners, Pierre Moustial, Samuel Levy, Alex Slack, Victor Decrion, Edoardo Fracchia, and others, has closed a €400 million health tech fund. 

Named Lauxera Growth II, the fund aims to transform Europe’s healthtech innovators into global leaders through a hands-on, operational approach that sets Lauxera apart from traditional investors.

Lauxera Growth II has already backed leading healthtech companies, including Germany’s Acandis, a developer of neurovascular devices with a presence in over 60 countries, and Sweden’s Antaros Medical, which leverages AI-powered imaging to streamline clinical trials in areas like obesity and immunology.

Unlike many European funds, Lauxera takes an operationally hands-on approach, helping portfolio companies navigate U.S. regulations, scale commercial operations, and expand globally. This model proved successful with OrganOx, acquired by Japan’s Terumo Group in August 2025 for $1.5 billion. Reviewing over 1,000 opportunities annually, and with a track record including Natural Cycles, the only FDA-approved non-hormonal contraception app, Lauxera continues to attract founders and investors aiming to scale beyond Europe. The fund remains open to new investors and plans to announce its next major investment, focusing on AI-driven diagnostics, smart medical devices, and platforms transforming healthcare delivery.